论文部分内容阅读
目的:探讨非诺贝特对糖尿病大鼠肾组织MCP-1、FN表达的影响。方法:选择健康雄性SD大鼠36只,随机分为正常对照组(NC组)、糖尿病模型组(DN组)和非诺贝特治疗组(DF组),每组12只,模型组及治疗组以链脲佐菌素诱发糖尿病,治疗组给予非诺贝特灌胃。分别于第4、8周观察各组大鼠脂代谢、血肌酐及24h尿蛋白定量。肾组织标本行免疫组化检测肾组织MCP-1、FN的表达水平。结果:模型组胆固醇、甘油三酯、肌酐及24h尿蛋白定量水平的表达水平较同期正常组(P<0.01)和治疗组(P<0.05)有明显的增加。模型组大鼠肾组织MCP-1、FN表达较同期正常组(P<0.001)和治疗组(P<0.01)有明显的增加。结论:非诺贝特可以下调糖尿病大鼠肾组织MCP-1、FN表达对试验性糖尿病大鼠具有部分肾保护作用。
Objective: To investigate the effects of fenofibrate on the expression of MCP-1 and FN in the kidney of diabetic rats. Methods: Thirty-six healthy male Sprague-Dawley rats were randomly divided into normal control group (NC group), diabetic model group (DN group) and fenofibrate treatment group (DF group), 12 rats in each group, model group and treatment Group with streptozotocin-induced diabetes, the treatment group given fenofibrate gavage. At the 4th and 8th weeks, the lipid metabolism, serum creatinine and urinary protein in 24 hours were observed. Immunohistochemistry was used to detect the expression of MCP-1 and FN in renal tissues. Results: The quantitative expression levels of cholesterol, triglyceride, creatinine and 24 h urinary protein in the model group were significantly increased compared with the normal group (P <0.01) and the treatment group (P <0.05). The expression of MCP-1 and FN in renal tissue of rats in model group were significantly increased compared with normal group (P <0.001) and treatment group (P <0.01). CONCLUSION: Fenofibrate can down-regulate the expression of MCP-1 and FN in renal tissue of diabetic rats with partial renal protective effect on experimental diabetic rats.